Characterising the treatment of thromboembolic events after COVID-19 vaccination in 4 European countries and the US: An international network cohort study

• DOI: 10.3389/fphar.2023.1118203
• Publication Date: 2023-03-24T04:44:48Z
• Authors: Aniek F. Markus; Victoria Y. Strauss; Edward Burn; Xintong Li; Antonella Delmestri; Christian Reich; Can Yin; Miguel A. Mayer; Juan-Manuel Ramír...; Edelmira Marti; Katia M. C. Verhamme; Peter R. Rijnbeek; Daniel Prieto-Alh...; Annika M. Jödicke
• Keywords: thromboembolic events; Pharmacology; Thromboembolic events; Epidemiology; Vaccination; COVID-19; RM1-950; vaccination; 3. Good health; Treatment pathways; Anticoagulation; SDG 3 - Good Health and Well-being; Drug utilization; epidemiology; Therapeutics. Pharmacology; treatment pathways; drug utilization; anticoagulation

Background: Thrombosis with thrombocytopenia syndrome (TTS) has been identified as a rare adverse event following some COVID-19 vaccines. Various guidelines have issued on the treatment of TTS. We aimed to characterize TTS and other thromboembolic events (venous thromboembolism (VTE), arterial (ATE) after vaccination compared historical (pre-vaccination) data in Europe US. Methods: conducted an international network cohort study using 8 primary care, outpatient, inpatient databases from France, Germany, Netherlands, Spain, The United Kingdom, States. investigated pathways diagnosis TTS, VTE, or ATE for pre-vaccination (background) (01/2017—11/2020), vaccinated people followed 28 days dose any vaccine recorded 12/2020 onwards). Results: Great variability was observed proportion treated (with recommended therapy) across databases, both before vaccination. Most patients received heparins, platelet aggregation inhibitors, direct Xa inhibitors. majority VTE (before vaccination) were first heparins settings inhibitors outpatient settings. In patients, treatments also similar vaccinations, prescribed most frequently. Inpatient claims showed substantial heparin use. Conclusion: similarly background events. Heparin use post-vaccine suggests not vaccine-induced thrombosis by treating clinicians.